The health care industry should take into account outcomes when weighing the cost of new treatments and technologies and make quality-adjusted life years (QALYs) part of the equation, say the authors of a study in the April issue of Health Affairs.
This is the begining of an article in Managed Care Magazine that reviews a paper I published in Health Affairs with co-authors Darius Lakdawalla, Claudio Luccarelli, Sean Nicholson, Zeba Khan and Tomas Philipson. The rest of the article is here or the original piece is here.